A rat study reports that spatially fractionated minibeam radiation preserved the efficacy of CD19-directed CAR T cells in a brain lymphoma model and extended survival compared with conventional radiotherapy (ID: b3ae98c1c1bde018). The preclinical result suggests that how dose is delivered to the brain microenvironment can affect the persistence and function of infused immune cells. Because CAR T timing and brain radiotherapy planning are major points of friction in clinical protocols, the study offers a concrete design variable—beam geometry—that future translational work can test. It also frames a potential path toward better synergy with less compromise to cell-based therapy. No clinical trial results were reported, but the evidence directly targets a sequencing and modality question that commonly drives regimen choices in practice.